GE
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer | Nature communications |  | 2026 | 1 | 0 | ||
| Neural anticipation of virtual infection triggers an immune response | Nature neuroscience | | 2025 | 44 | 26 | ||
| Gliadin-reactive vitamin D-sensitive proinflammatory ILCPs are enriched in celiac patients | Cell reports | | 2022 | 246 | 175 | ||
| c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells | EMBO journal | | 2022 | 383 | 468 | ||
| PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions | Nature Communications | | 2021 | 357 | 262 | ||
| Healthy and patient type 2 innate lymphoid cells are differently affected by in vitro culture conditions | Journal of Asthma and Allergy | | 2021 | 247 | 88 | ||
| Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer | Science Advances | | 2021 | 496 | 361 | ||
| Human primed ILCPs support endothelial activation through NF-κB signaling | eLife | | 2021 | 356 | 198 | ||
| Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells | Journal of Leukocyte Biology | | 2020 | 412 | 272 | ||
| Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma | Cancer Immunology Research |  | 2020 | 621 | 4 | ||
| ILC2s: new actors in tumor immunity | Frontiers in Immunology | | 2019 | 416 | 198 | ||
| Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells | Journal for Immunotherapy of Cancer | | 2019 | 369 | 174 |
